(Q35605450)

9 August 2017

1 reference

title

Aromatase inhibitors for breast cancer: lessons from the laboratory (English)

1 reference

9 August 2017

1 reference

1 reference

2

Mitch Dowsett

1 reference

9 August 2017

Stephen R D Johnston

1

1 reference

PubMed ID

14668813

9 August 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

9 August 2017

Nature Reviews Cancer

1 reference

9 August 2017

3

1 reference

9 August 2017

821-831

1 reference

9 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc1211

9 August 2017

0 references

cites work

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

31 March 2020

1 reference

Overview of the main outcomes in breast-cancer prevention trials

31 March 2020

1 reference

Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators

31 March 2020

1 reference

Endocrine-responsive breast cancer and strategies for combating resistance

31 March 2020

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

31 March 2020

1 reference

Aromatase inhibitors in breast cancer

31 March 2020

1 reference

Functional domains of the human estrogen receptor

31 March 2020

1 reference

Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling

31 March 2020

1 reference

Selective estrogen receptor modulators: structure, function, and clinical use.

31 March 2020

1 reference

Selective oestrogen receptor modulation: molecular pharmacology for the millennium

31 March 2020

1 reference

Molecular basis of agonism and antagonism in the oestrogen receptor

31 March 2020

1 reference

The human estrogen receptor has two independent nonacidic transcriptional activation functions

31 March 2020

1 reference

31 March 2020

1 reference

Aromatase and its inhibitors: significance for breast cancer therapy

31 March 2020

1 reference

Aromatase and its inhibitors: new biology and clinical perspectives

31 March 2020

1 reference

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies

31 March 2020

1 reference

A rare CYP19 (aromatase) variant may increase the risk of breast cancer

31 March 2020

1 reference

Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk.

31 March 2020

1 reference

The importance of local synthesis of estrogen within the breast

31 March 2020

1 reference

Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis

31 March 2020

1 reference

Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators

31 March 2020

1 reference

4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer

31 March 2020

1 reference

Pharmacology and clinical experience with exemestane

31 March 2020

1 reference

Theoretical considerations for the ideal aromatase inhibitor

31 March 2020

1 reference

Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat.

31 March 2020

1 reference

Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.

31 March 2020

1 reference

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

31 March 2020

1 reference

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

31 March 2020

1 reference

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

31 March 2020

1 reference

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer

31 March 2020

1 reference

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

31 March 2020

1 reference

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

31 March 2020

1 reference

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

31 March 2020

1 reference

Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

31 March 2020

1 reference

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

31 March 2020

1 reference

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

31 March 2020

1 reference

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

31 March 2020

1 reference

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

31 March 2020

1 reference

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

31 March 2020

1 reference

The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain

31 March 2020

1 reference

Screening for ESR mutations in breast and ovarian cancer patients

31 March 2020

1 reference

Oestrogen receptor mutants and variants in breast cancer

31 March 2020

1 reference

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo

31 March 2020

1 reference

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

31 March 2020

1 reference

Estrogen receptor pathways to AP-1.

31 March 2020

1 reference

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

31 March 2020

1 reference

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

31 March 2020

1 reference

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

31 March 2020

1 reference

Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

31 March 2020

1 reference

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

31 March 2020

1 reference

Proximal events in signaling by plasma membrane estrogen receptors

31 March 2020

1 reference

Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor

31 March 2020

1 reference

Estradiol rapidly activates Akt via the ErbB2 signaling pathway.

31 March 2020

1 reference

AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor

31 March 2020

1 reference

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

31 March 2020

1 reference

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

31 March 2020

1 reference

Analysis of the aromatase cytochrome P450 gene in human breast cancers

31 March 2020

1 reference

Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients

31 March 2020

1 reference

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation

31 March 2020

1 reference

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

31 March 2020

1 reference

Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells

31 March 2020

1 reference

Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells

31 March 2020

1 reference

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

31 March 2020

1 reference

The pharmacology of letrozole

31 March 2020

1 reference

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

31 March 2020

1 reference

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group

31 March 2020

1 reference

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1211

1 reference

9 August 2017

1 reference

PubMed ID

14668813